EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety, Pharmacokinetics, and Pharmacodynamics of Supratherapeutic Multiple Doses of Iptacopan in Healthy Participants: A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Study

Kenneth Kulmatycki, Marie-Anne Valentin, Melissa Hackling, Mohammed Hisham Mecheri, Suleyman Eralp Bellibas, Bharti Shah, Robert Schmouder

European Journal of Drug Metabolism and Pharmacokinetics · 14.11.2026

DOI: 10.1007/s13318-026-01043-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Drug Metabolism and Pharmacokinetics, online erschienen am 14.11.2026. Verfasst von Kenneth Kulmatycki und 6 weiteren Autor:innen. Beteiligte Einrichtung: Novartis BioMedical Research, Cambridge, MA, USA. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma AG.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Iptacopan is an orally administered proximal complement inhibitor targeting factor B to selectively inhibit the alternative pathway of the complement system, while sparing activity of the classical pathway. Previous studies have shown that iptacopan is rapidly absorbed, reaching maximum concentration in approximately 1–2 h, and that dose–exposure proportionality is achieved after multiple doses of 100 mg and 200 mg twice daily (BID). The approved clinical dose is 200 mg BID. This study evaluated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of multiple supratherapeutic doses of iptacopan (400 and 800 mg BID) in healthy adult participants.

Methods

The trial was a randomized, placebo-controlled, double-blinded phase 1 multiple-ascending-dose study conducted in two sequential cohorts.

Results

A total of 26 participants were randomized 2:1 to BID iptacopan 400 mg or 800 mg for 14 days or matching placebo; 24 participants completed the study. Treatment-emergent adverse events (TEAEs) were mild to moderate, and there were no serious AEs, deaths, or discontinuations due to AEs. The most frequent TEAE was headache, occurring in five (20.8%) participants. Plasma measures of iptacopan exposure appeared to increase in a dose-proportional manner, and biomarker analyses showed that there was rapid, near-complete, and persistent inhibition of alternative pathway activity for both doses, measured by the Wieslab assay.

Conclusions

These findings show that iptacopan supratherapeutic doses of 400 mg and 800 mg BID are well tolerated in healthy participants and describe the PK and PD properties of iptacopan and inhibition of the alternative complement pathway.

Autor:innen und Institutionen

  • Novartis BioMedical Research, Cambridge, MA, USA.
  • Novartis BioMedical Research, Basel, Switzerland.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Novartis Healthcare Pvt. Ltd, Hyderabad, India.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. robert.schmouder@novartis.com.

Förderung

  • Novartis Pharma AG

Zitieren

APA

Kulmatycki, K., Valentin, M. A., Hackling, M., Mecheri, M. H., Bellibas, S. E., Shah, B., & Schmouder, R. (2026). Safety, Pharmacokinetics, and Pharmacodynamics of Supratherapeutic Multiple Doses of Iptacopan in Healthy Participants: A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Study. European Journal of Drug Metabolism and Pharmacokinetics. https://doi.org/10.1007/s13318-026-01043-9

Vancouver

Kulmatycki K, Valentin MA, Hackling M, Mecheri MH, Bellibas SE, Shah B, et al. Safety, Pharmacokinetics, and Pharmacodynamics of Supratherapeutic Multiple Doses of Iptacopan in Healthy Participants: A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Study. European Journal of Drug Metabolism and Pharmacokinetics. 2026. doi:10.1007/s13318-026-01043-9

BibTeX
@article{Kulmatycki2026,
  author = {Kulmatycki, Kenneth and Valentin, Marie-Anne and Hackling, Melissa and Mecheri, Mohammed Hisham and Bellibas, Suleyman Eralp and Shah, Bharti and Schmouder, Robert},
  title = {Safety, Pharmacokinetics, and Pharmacodynamics of Supratherapeutic Multiple Doses of Iptacopan in Healthy Participants: A Phase 1 Randomized, Double-Blinded, Placebo-Controlled Study},
  journal = {European Journal of Drug Metabolism and Pharmacokinetics},
  year = {2026},
  doi = {10.1007/s13318-026-01043-9}
}
Kostenlos starten →